Amgen and Pfizer's PCSK9 inhibitors step hopefully 'down the line'
This article was originally published in Scrip
Executive Summary
Further Phase II data supporting a strong efficacy profile for Amgen’s and Pfizer’s PCSK9 inhibitors –AMG 145 and RN316 (PF-04950615) – generated excitement at the American Heart Association meeting in Los Angeles as they make a compelling clinical case for the drugs’ additive effect to statins, raising the hope that in future most patients will be able to reach their LDL-cholesterol goals with this new drug class.